President Trump announced a drug pricing executive order on April 15 aiming to lower prescription drug prices through transparent, linear pricing mechanisms1
The TrumpRx.gov platform launched in February 2026, allowing patients to access drugs at Most-Favored-Nation prices in line with lowest prices paid by other developed nations3
Historic price reductions were negotiated for major drugs:
Ozempic and Wegovy prices fell from $1,000-$1,350 per month to $350, while Zepbound dropped from $1,086 to $346 per month2
As of March 2026, 16 major pharmaceutical manufacturers including AstraZeneca, Eli Lilly, Novo Nordisk, and Pfizer have reached MFN pricing deals with the Trump Administration3
The CY 2026 Medicare Part D out-of-pocket maximum cap is $2,100, with a deductible of $6151
Trump's executive order seeks to end the 'pill penalty' by aligning timelines for small-molecule drugs and biologics in Medicare price negotiations1
The FDA was directed to accelerate approval of generics, biosimilars, and competition drugs, which may impact long-term forecasts for pharmaceutical manufacturers1
Pharmaceutical companies raised list prices on 872 brand-name medications with a median 4% increase in 2026 despite negotiated price reductions7
The negotiated prices are expected to reduce out-of-pocket spending by approximately $1.5 billion in 20266
Sources:
1. https://www.integrichain.com/blog/unpacking-part-d-redesign-in-2026-and-trumps-drug-pricing-executive-order/
2. https://www.whitehouse.gov/fact-sheets/2025/11/fact-sheet-president-donald-j-trump-announces-major-developments-in-bringing-most-favored-nation-pricing-to-american-patients/
3. https://www.whitehouse.gov/fact-sheets/2026/02/fact-sheet-president-donald-j-trump-launches-trumprx-gov-to-bring-lower-drug-prices-to-american-patients/
6. https://medicare.chir.georgetown.edu/drug-pricing-in-the-era-of-trump-2-0/
7. https://www.pharmexec.com/view/companies-raise-list-prices-16-agreements-lower-prices-trump-administration-report